Tatva Chintan Pharma Chem (NSE:TATVA) Interest Expense: ₹-45 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:TATVA Tatva Chintan Pharma Chem Ltd NSE:TATVA
82 GF Score
Price ₹1,788.20
GF Value ₹1,502.93
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Tatva Chintan Pharma Chem Interest Expense?

Tatva Chintan Pharma Chem NSE:TATVA +6.43% 82 Interest Expense is ₹-45 Mil as of Jun. 2026. GuruFocus rates NSE:TATVA with a GF Score™ of 82/100 and a GF Value™ of ₹1,502.93 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Tatva Chintan Pharma Chem's interest expense for the three months ended in Jun. 2026 was ₹ -21 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-45 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Tatva Chintan Pharma Chem's Operating Income for the three months ended in Jun. 2026 was ₹ 217 Mil. Tatva Chintan Pharma Chem's Interest Expense for the three months ended in Jun. 2026 was ₹ -21 Mil. Tatva Chintan Pharma Chem's Interest Coverage for the quarter that ended in Jun. 2026 was 10.44. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Tatva Chintan Pharma Chem  (NSE:TATVA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tatva Chintan Pharma Chem's Interest Expense for the three months ended in Jun. 2026 was ₹-21 Mil. Its Operating Income for the three months ended in Jun. 2026 was ₹217 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was ₹0 Mil.

Tatva Chintan Pharma Chem's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Jun. 2026 )/Interest Expense (Q: Jun. 2026 )
=-1*217.3/-20.81
=10.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Tatva Chintan Pharma Chem Interest Expense Historical Data

* Premium members only.

The historical data trend for Tatva Chintan Pharma Chem's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tatva Chintan Pharma Chem Interest Expense Chart

Tatva Chintan Pharma Chem Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial -43.51 -79.97 -61.51 -12.90 -28.51

Tatva Chintan Pharma Chem Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.13 -5.07 -4.93 -14.38 -20.81
NSE:TATVA
82GF Score
Tatva Chintan Pharma Chem Ltd NSE:TATVA
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tatva Chintan Pharma Chem Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-45 Mil mean?
Tatva Chintan Pharma Chem (NSE:TATVA) has a Interest Expense of ₹-45 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tatva Chintan Pharma Chem and its competitors.
Is Tatva Chintan Pharma Chem's Interest Expense too high?
Tatva Chintan Pharma Chem's current Interest Expense is ₹-45 Mil. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's Interest Expense compare to LIN and SHW?
Tatva Chintan Pharma Chem's Interest Expense of ₹-45 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Chemicals company?
A good Interest Expense depends on the Chemicals industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Tatva Chintan Pharma Chem and its competitors. Tatva Chintan Pharma Chem's current Interest Expense is ₹-45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,502.93, compared to a current price of ₹1,788.20 — trading 19% above its estimated fair value. The current Interest Expense is ₹-45 Mil. Tatva Chintan Pharma Chem's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current Interest Expense is ₹-45 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?

Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be overvalued. The current stock price of ₹1,788.20 is trading 19% above its estimated GF Value™ of ₹1,502.93. GuruFocus considers Tatva Chintan Pharma Chem to be Modestly Overvalued.

Key valuation signals for NSE:TATVA:

  • Interest Expense: ₹-45 Mil
  • GF Value™: ₹1,502.93 vs. price of ₹1,788.20 (19% above fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tatva Chintan Pharma Chem Business Description

Other Exchanges 543321:India
Address Plot No. 353, Makarpura GIDC, Vadodara, GJ, IND, 390010
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
82GF Score

Get the complete analysis for NSE:TATVA

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,788.20
Price
₹1,502.93
GF Value